TY - JOUR
T1 - American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis— 2020 Update Executive Summary
AU - Camacho, Pauline M.
AU - Petak, Steven M.
AU - Binkley, Neil
AU - Diab, Dima L.
AU - Eldeiry, Leslie S.
AU - Farooki, Azeez
AU - Harris, Steven T.
AU - Hurley, Daniel L.
AU - Kelly, Jennifer
AU - Lewiecki, E. Michael
AU - Pessah-Pollack, Rachel
AU - McClung, Michael
AU - Wimalawansa, Sunil J.
AU - Watts, Nelson B.
N1 - Funding Information:
Neil Binkley, MD: Amgen, consultant; Radius Health, GE Healthcare, research grant support.
Funding Information:
The American Association of Clinical Endocrinologists' Medical Guidelines for Practice are systematically developed statements to assist health-care professionals in medical decision-making for specific clinical conditions. Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflect the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. We encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made considering local resources and individual patient circumstances. DISCLOSURE Co-Chairs Pauline Camacho, MD, FACE: Amgen Inc and Shire, Principal Investigator, research grant support. Steven M. Petak, MD, JD, FACP, FCLM, MACE, CCD: NASA-JSC, consultant; Takeda, Alexion, Amgen, Radius, speaker. Task Force Members Neil Binkley, MD: Amgen, consultant; Radius Health, GE Healthcare, research grant support. Dima L. Diab, MD, FACE, FACP, CCD; Leslie S. Eldeiry, MD; Daniel L. Hurley, MD, FACP; Jennifer Kelly, DO, FACE; and Sunil J. Wimalawansa, MD, PhD, MBA, FCCP, FACP, FRCP, DSc, FACE: The authors have no multiplicity of interest to disclose. Azeez Farooki, MD: Alexion, Novo Nordisk, Novartis, Sanofi, Genentech, consultant; Amgen, Alexion, speaker; Johnson & Johnson, stock owner. Steven T. Harris, MD, FACP: Myovant Sciences, Radius Health, Shire, consultant; Eli Lilly & Company, Amgen, Radius Health, speaker. E. Michael Lewiecki, MD, FACE, FACP, CCD: Amgen, Radius Health, Alexion, Samsung Bioepis, Sandoz, consultant; Radius, Alexion, speaker; Radius Health, Amgen, Mereo, Bindex, research grant support. Rachel Pessah-Pollack, MD, FACE: Boehringer Ingelheim/Eli Lilly, speaker and advisor; Sanofi, consultant; Radius, advisor. Michael McClung, MD, FACP, FACE: Amgen, Myovant, consultant; Amgen, speaker. Nelson B. Watts, MD, FACP, CCD, FASBMR, MACE: Amgen, AbbVie, Sanofi, consultant; Amgen, Radius, speaker. Reviewers Donald A. Bergman, MD: Clinical Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Bergman has no multiplicity of interest to disclose. Paul D. Miller, MD: Distinguished Clinical Professor of Medicine, University of Colorado Health Sciences Center, Medical Director, Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, CO. Dr. Miller has received research grants from Alexion and Radius Health.
Funding Information:
Pauline Camacho, MD, FACE: Amgen Inc and Shire, Principal Investigator, research grant support.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/5
Y1 - 2020/5
N2 - Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols. Results: The Executive Summary of this 2020 updated guideline contains 52 recommendations: 21 Grade A (40%), 24 Grade B (46%), 7 Grade C (14%), and no Grade D (0%). These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 368 citations: 123 (33.5%) evidence level (EL) 1 (highest), 132 (36%) EL 2 (intermediate), 20 (5.5%) EL 3 (weak), and 93 (25%) EL 4 (lowest). New or updated topics in this CPG include: clarification of the diagnosis of osteoporosis, stratification of the patient according to high-risk and very-high-risk features, a new dual-action therapy option, and transitions from therapeutic options. Conclusion: This guideline is a practical tool for endocrinologists, physicians in general, regulatory bodies, health-related organizations, and interested laypersons regarding the diagnosis, evaluation, and treatment of post-menopausal osteoporosis.
AB - Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols. Results: The Executive Summary of this 2020 updated guideline contains 52 recommendations: 21 Grade A (40%), 24 Grade B (46%), 7 Grade C (14%), and no Grade D (0%). These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 368 citations: 123 (33.5%) evidence level (EL) 1 (highest), 132 (36%) EL 2 (intermediate), 20 (5.5%) EL 3 (weak), and 93 (25%) EL 4 (lowest). New or updated topics in this CPG include: clarification of the diagnosis of osteoporosis, stratification of the patient according to high-risk and very-high-risk features, a new dual-action therapy option, and transitions from therapeutic options. Conclusion: This guideline is a practical tool for endocrinologists, physicians in general, regulatory bodies, health-related organizations, and interested laypersons regarding the diagnosis, evaluation, and treatment of post-menopausal osteoporosis.
UR - http://www.scopus.com/inward/record.url?scp=85084962817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084962817&partnerID=8YFLogxK
U2 - 10.4158/GL-2020-0524
DO - 10.4158/GL-2020-0524
M3 - Article
C2 - 32427525
AN - SCOPUS:85084962817
VL - 26
SP - 564
EP - 570
JO - Endocrine Practice
JF - Endocrine Practice
SN - 1530-891X
IS - 5
ER -